

Performance in Delivering Clinical Trial Research Q4 2017 - 2018  
Time to Target (Commercial Contracts)  
Studies that have Closed to Recruitment in the Previous 12 months

Research Ethics Number	IRAS number	Name of Trial	Agreed Target of patients	Target Range Agreed? (min/max)	Target Date Agreed?	Total Recruited by Agreed Target Date	Total Number of Study Participants Recruited	Recruitment end date	Trial Status	Target met	Comments
15/SC/0432	181387	A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Treatment-resistant Depression	2	Yes (2/2)	Yes (24/05/2017)	0	0	24/05/2017	Withdrawn By Sponsor	No	Sponsor terminated recruitment early due to global target being met
16/SC/0363	205067	RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE (STEADFAST)	3	Yes (3/3)	Yes (28/04/2017)	5	5	10/04/2017	Recruitment Finished	Yes	
16/LO/1820	212826	Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa (OPIANT)	10	Yes (10/10)	Yes (31/01/2018)	0	0	09/11/2017	Withdrawn By Sponsor	No	Study terminated following discussions between site and sponsor due to unforeseen circumstances regarding staff shortages in very small department
16/LO/1086	203002	A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder	3	Yes (3/3)	Yes (31/10/2017)	1	1	31/12/2017	Recruitment Finished	No	Difficult study to recruit to nationally and only 1 site managed to recruit target
16/SC/0435	212314	54135419TRD3008 An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression Safety and Sustainance of Esketamine Treatment Response With Repeated Doses at Intervals Determined by Symptom Severity (SUSTAIN-	2	Yes (2/2)	Yes (31/03/2018)	2	2	31/08/2017	Recruitment Finished	Yes	